Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products

  Mylan Enhances Partnership with Biocon through Strategic Collaboration for
                               Insulin Products

PR Newswire

PITTSBURGH, Feb. 13, 2013

PITTSBURGH, Feb. 13, 2013 /PRNewswire/ --Mylan (Nasdaq: MYL) today announced
that it has entered into a definitive agreement with Biocon Limited for an
exclusive strategic collaboration on the development and commercialization of
generic versions of three insulin analog products. 

Mylan CEO Heather Bresch commented, "This collaboration builds off of our
existing successful partnership for generic biologics with Biocon and brings
Mylan a portfolio of high-value insulin analog products. This collaboration
further expands and diversifies our pipeline of complex,
difficult-to-manufacture products with strong future growth potential.
Importantly, we believe we have the opportunity to be one of the first generic
entrants in developed markets into the rapidly growing diabetes area, helping
to address unmet needs and reduce the economic burden to those battling the
disease and to the global healthcare system."

Mylan President Rajiv Malik added, "Biocon has served as a trusted development
partner for the past three years, and we are very excited about this expanded
relationship. Our thorough review of the development work completed by Biocon
to date on these products gives us great confidence in the company's
capabilities in this area and in the quality and value of this program. Our
confidence in the potential of this program is supported by our proven ability
to drive value from our partnership with Biocon and we believe Mylan is
uniquely positioned to work with Biocon to bring these products to market."

Biocon's Chairman & Managing Director, Kiran Mazumdar-Shaw said, "Mylan is a
natural preferred partner for our portfolio of generic insulin analogs and
this collaboration only further strengthens our existing successful
partnership. We are excited to team up with Mylan to be able to cost
effectively address the disease and economic burden that diabetes poses to
global health. We are confident that together we can build a strong global
presence in generic insulin analogs and provide access to affordable therapy
options to physicians, healthcare providers and diabetes patients worldwide."

Under the terms of this collaboration, Mylan will have the rights to develop
and market Biocon's Glargine (the generic version of Sanofi's Lantus®), Lispro
(the generic version of Eli Lilly and Company's Humalog®) and Aspart (the
generic version of Novo Nordisk's NovoLog®). Mylan and Biocon will share
development, capital and certain other costs to bring the products to market.
Mylan will have exclusive commercialization rights in the U.S., Canada,
Australia, New Zealand, the European Union and the European Free Trade
Association countries through a profit-share arrangement with Biocon. Mylan
will have co-exclusive commercialization rights with Biocon in certain other
markets around the world. All other transaction terms remain confidential.

According to public filings, reported worldwide net sales of Lantus, Humalog
and NovoLog for 2012 were approximately $11.5 billion.

This press release includes statements that constitute "forward-looking
statements," including with regard to the collaboration and commercialization
of the products and the company's future opportunities. These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because such statements inherently involve
risks and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to:
the content and timing of decisions by regulatory authorities related to the
development and commercialization of the products; difficulties or delays in
manufacturing; demand for and market acceptance for the products; the impact
of competitive products and pricing; and the other risks detailed in the
company's periodic filings with the Securities and Exchange Commission. The
company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which more than one-third of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

About Biocon Limited
Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN
Id: INE376G01013) is India's largest biotechnology company by revenue. The
Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated,
innovation-driven healthcare enterprise with strategic focus on
biopharmaceuticals and research services. Biocon's value chain traverses the
entire length of discovery, development and commercialization of novel
therapeutics. Biocon delivers affordable solutions to partners and customers
in over 75 countries across the globe. Biocon's robust product offering
includes the world's first Pichia-based recombinant human Insulin, INSUGEN(R),
Glargine, BASALOG® and India's first indigenously produced monoclonal antibody
BIOMAb-EGFR(TM) for head and neck cancer.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), +1-724-514-1968; or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.